论文部分内容阅读
目的探讨组胺Ｈ１和Ｈ２受体拮抗剂联合使用治疗Ⅰ型过敏性疾病的可行性。方法对三组志愿者（每组１２人）分别服用息斯敏１０ｍｇ，１次／ｄ；息斯敏１０ｍｇ和雷尼替丁３００ｍｇ，各１次／ｄ，息斯敏１０ｍｇ，１次／ｄ和雷尼替丁３００ｍｇ，每１２ｈ１次。５天后停雷尼替丁，继续服用息斯敏２天。第１～５天，每日比较服药前和服药后第３ｈ、第６ｈ组胺（１００μｇ）诱导即刻型皮肤（风团和红晕）的反应强度（％）。第８天组胺皮试重复１次。结果息斯敏１０ｍｇ，１次／ｄ和雷尼替丁３００ｍｇ，每１２ｈ１次组对组胺诱导皮肤风团和红晕的反应强度在各个时间点均明显低于息斯敏１０ｍｇ，１次／ｄ组，统计学处理除第２次服药前风团强度无显著性差异外（Ｐ＞０．０５），其它各时间点均有显著性差异（Ｐ＜０．０１或＜０．０５）。结论息斯敏联合雷尼替丁与息斯敏单独使用相比，明显加快和加强组胺诱导皮肤反应抑制作用，该方案为临床治疗Ⅰ型过敏反应性疾病提供了可行性依据。
Objective To investigate the feasibility of combined use of histamine H1 and H2 receptor antagonists in the treatment of type Ⅰ allergic diseases. Methods Three groups of volunteers (12 in each group) were treated with astemizole 10 mg once daily, astemizine 10 mg, ranitidine 300 mg, once daily, astemizole 10 mg, once daily And ranitidine 300mg, every 12h1 times. After 5 days, ranitidine, continue taking astemizole 2 days. Day 1 to day 5, histamine (100μg) induced immediate skin (wind group and flush) reaction intensity (%) at 6h before taking medicine and 3h after taking medicine. On the 8th histamine skin test repeated 1 times. Results Astemizole 10mg, once a day and ranitidine 300mg, every 12h1 times group histamine induced skin regurgitation and flushing intensity at all time points were significantly lower than asosmin 10mg, 1 times / d There was significant difference (P <0.01 or <0.05) among the other time points except for the strength of the wind group before the second treatment. There was no significant difference between the two groups (P> 0.05). CONCLUSION: Aspirin combined with ranitidine significantly and speedily suppressed histamine-induced skin reaction inhibition compared with astemizole alone. This protocol provides a feasible basis for the clinical treatment of type I allergic reactions.